Log In
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?
Log In
Don't have an account? Sign Up Here
Join Us
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
I agree to TheMaven's
Terms
and
Policy
Sign Up
Already have an account? Login here
JIM CRAMER
INVESTING
PERSONAL FINANCE
RETIREMENT
CRYPTO
MARKETS
HOW-TO
VIDEO
FINANCIAL ADVISOR CENTER
TECHNOLOGY
Search
Trade with Jim Cramer 14 Days Free
Join the Action Alerts PLUS Community today!
SUBSCRIBE NOW
LATEST NEWS
INVESTING
5 Top Stock Gainers for Wednesday: Carnival, XL Fleet, Ouster
By Rob Lenihan
Apr 7, 2021 4:26 PM EDT
PRESS RELEASES
Biohaven Announces Preliminary 1Q2021 Net Product Revenue For NURTEC ODT
By PR Newswire
Apr 7, 2021 7:30 AM EDT
PRESS RELEASES
Rick Ware Racing, Biohaven's Nurtec ODT And Nine Line Apparel Honor Fallen Service Members
By PR Newswire
Apr 6, 2021 7:30 AM EDT
PRESS RELEASES
Biohaven Enrolls First Patient In Phase 2/3 Trial Of Oral Zavegepant, Prompting $100 Million Milestone Funding Payment From Royalty Pharma
By PR Newswire
Mar 29, 2021 7:30 AM EDT
JIM CRAMER
'Mad Money' Lightning Round: Marvell Tech, Lithia, more
By Scott Rutt
Mar 23, 2021 8:00 AM EDT
JIM CRAMER
Countertrend Rally: Cramer's 'Mad Money' Recap (Monday 3/22/21)
By Scott Rutt
Mar 22, 2021 10:56 PM EDT
PRESS RELEASES
Biohaven Announces Pricing Of $200 Million Public Offering Of Common Shares
By PR Newswire
Mar 15, 2021 10:16 PM EDT
PRESS RELEASES
Biohaven Announces Proposed Public Offering Of Common Shares
By PR Newswire
Mar 15, 2021 4:32 PM EDT
PRESS RELEASES
Biohaven To Report Fourth Quarter And Full Year 2020 Financial Results And Recent Business Developments On March 1, 2021
By PR Newswire
Feb 23, 2021 6:40 PM EST
PRESS RELEASES
Biohaven's BHV-1200, A Multimodal Antibody Therapy Enhancer (MATE), Demonstrates Effective Neutralization Of Multiple Strains Of COVID-19
By PR Newswire
Feb 22, 2021 7:30 AM EST
PRESS RELEASES
Biohaven Provides Update On ESG Practices
By PR Newswire
Feb 8, 2021 7:30 AM EST
PRESS RELEASES
Biohaven Signs Cody Ware As Driver For Nurtec® ODT Chevrolet For The 2021 NASCAR Cup Series Season
By PR Newswire
Jan 18, 2021 10:10 AM EST
PRESS RELEASES
Biohaven Provides Update On Phase 2/3 Trial And Alzheimer's Disease Program
By PR Newswire
Jan 18, 2021 9:00 AM EST
JIM CRAMER
Markets Stay the Course: Cramer's 'Mad Money' Recap (Thursday 1/7/21)
By Scott Rutt
Jan 7, 2021 8:38 PM EST
PRESS RELEASES
Biohaven Acquires Kleo Pharmaceuticals And Licenses Platform Technology From Yale University To Form Biohaven Labs
By PR Newswire
Jan 7, 2021 7:30 AM EST
PRESS RELEASES
Biohaven's Nurtec® ODT Partners With Rick Ware Racing For 24 Hours Of Daytona Entry
By PR Newswire
Jan 5, 2021 10:00 AM EST
PRESS RELEASES
Biohaven Begins Pivotal Phase 3 Trial Of Troriluzole In Obsessive-Compulsive Disorder
By PR Newswire
Jan 4, 2021 7:30 AM EST
HEALTH
Top Biotech Stocks to Buy for 2021
By Bret Jensen
Mar 2, 2021 9:41 AM EST
PRESS RELEASES
Biohaven's Nurtec™ ODT Partners With The Rick Ware Racing Team In The 2021 NASCAR Cup Series
By PR Newswire
Dec 2, 2020 10:05 AM EST
PRESS RELEASES
Sosei Heptares And Biohaven Enter Global Collaboration And License Agreement To Advance Novel Small-Molecule CGRP Antagonist Portfolio
By PR Newswire
Dec 1, 2020 3:05 AM EST
JIM CRAMER
Escaping the Index: Cramer's 'Mad Money' Recap (Wednesday 11/18/20)
By Scott Rutt
Nov 18, 2020 9:22 PM EST
PRESS RELEASES
Biohaven Pharmaceuticals Inaugural Partner Of National Ataxia Foundation's Drug Development Collaborative
By PR Newswire
Nov 11, 2020 4:30 PM EST
PRESS RELEASES
Biohaven To Report Third Quarter 2020 Financial Results And Recent Business Developments On November 9, 2020
By PR Newswire
Oct 30, 2020 6:23 PM EDT
PRESS RELEASES
BioShin, Biohaven's Asia-Pacific Subsidiary, Raises $60M In Series A Funding To Advance Neuroscience Pipeline In Asia-Pacific Region
By PR Newswire
Sep 28, 2020 7:00 AM EDT
PRESS RELEASES
Biohaven's Oral Zavegepant, A Third Generation CGRP Receptor Antagonist, Receives Authorization To Proceed From FDA And Achieves First In Human Dosing
By PR Newswire
Sep 10, 2020 7:00 AM EDT
